Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease

Author(s): Sandra Rocha

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 37 , 2013

Become EABM
Become Reviewer
Call for Editor


The discovery of drugs for Alzheimer’s disease (AD) therapy that can also permeate the blood brain barrier (BBB) is very difficult owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly into the brain is not an option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. A promising approach for drug systemic delivery to the central nervous system is the use of nanosized carriers. The therapeutic potential of certain nanopharmaceuticals for AD has already been demonstrated in vivo after systemic delivery. They are based on i) conjugates of drug and monoclonal antibodies against BBB endogenous receptors; ii) cationized or end terminal protected proteins/peptides; iii) liposomes and polymeric nanoparticles coated with polysorbate 80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further validation of these systems are needed.

Keywords: Alzheimer’s disease, Brain drug-targeting, blood brain barrier, parenteral route administration, monoclonal antibodies, liposomes, polymeric nanoparticles, therapeutic peptides.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 26 September, 2013
Page: [6635 - 6646]
Pages: 12
DOI: 10.2174/13816128113199990613
Price: $65

Article Metrics

PDF: 70